Avelumab for untreated metastatic Merkel cell carcinoma – guidance (TA691)

Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease. It is recommended only if the company provides avelumab according to the commercial arrangement.

National Institute for Health and Care Excellence